Schedule of Segment Reporting Information, by Segment [Table Text Block] |
The following financial information represents the operating results of the reportable segments of the Company:
Three months ended October 31, 2017 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
20,334 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
20,334 |
|
Product revenues |
|
|
— |
|
|
$ |
7,081 |
|
|
|
— |
|
|
|
— |
|
|
|
7,081 |
|
Royalty and license fee income |
|
|
— |
|
|
|
261 |
|
|
|
— |
|
|
|
— |
|
|
|
261 |
|
|
|
|
20,334 |
|
|
|
7,342 |
|
|
|
— |
|
|
|
— |
|
|
|
27,676 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
12,042 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
12,042 |
|
Cost of product revenues |
|
|
— |
|
|
|
3,389 |
|
|
|
— |
|
|
|
— |
|
|
|
3,389 |
|
Research and development |
|
|
— |
|
|
|
523 |
|
|
$ |
224 |
|
|
|
— |
|
|
|
747 |
|
Selling, general and administrative |
|
|
6,095 |
|
|
|
2,614 |
|
|
|
— |
|
|
$ |
2,182 |
|
|
|
10,891 |
|
Provision for uncollectible accounts receivable |
|
|
800 |
|
|
|
14 |
|
|
|
— |
|
|
|
— |
|
|
|
814 |
|
Legal fee expense |
|
|
13 |
|
|
|
3 |
|
|
|
— |
|
|
|
415 |
|
|
|
431 |
|
Total operating costs and expenses |
|
|
18,950 |
|
|
|
6,543 |
|
|
|
224 |
|
|
|
2,597 |
|
|
|
28,314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
1,384 |
|
|
|
799 |
|
|
|
(224 |
) |
|
|
(2,597 |
) |
|
|
(638 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(25 |
) |
|
|
12 |
|
|
|
— |
|
|
|
170 |
|
|
|
157 |
|
Other |
|
|
14 |
|
|
|
7 |
|
|
|
— |
|
|
|
15 |
|
|
|
36 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(195 |
) |
|
|
— |
|
|
|
— |
|
|
|
(195 |
) |
Income (loss) before income taxes |
|
$ |
1,373 |
|
|
$ |
623 |
|
|
$ |
(224 |
) |
|
$ |
(2,412 |
) |
|
$ |
(640 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
404 |
|
|
$ |
326 |
|
|
$ |
— |
|
|
$ |
19 |
|
|
$ |
749 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
32 |
|
|
$ |
23 |
|
|
|
— |
|
|
$ |
150 |
|
|
|
205 |
|
Total |
|
$ |
32 |
|
|
$ |
23 |
|
|
$ |
— |
|
|
$ |
150 |
|
|
$ |
205 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
418 |
|
|
$ |
43 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
461 |
|
Three months ended October 31, 2016 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
18,558 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
18,558 |
|
Product revenues |
|
|
— |
|
|
$ |
7,426 |
|
|
|
— |
|
|
|
— |
|
|
|
7,426 |
|
Royalty and license fee income |
|
|
— |
|
|
|
300 |
|
|
|
— |
|
|
|
— |
|
|
|
300 |
|
|
|
|
18,558 |
|
|
|
7,726 |
|
|
|
— |
|
|
|
— |
|
|
|
26,284 |
|
Operating costs, expenses and legal settlements, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
10,896 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,896 |
|
Cost of product revenues |
|
|
— |
|
|
|
3,309 |
|
|
|
— |
|
|
|
— |
|
|
|
3,309 |
|
Research and development |
|
|
— |
|
|
|
627 |
|
|
$ |
195 |
|
|
|
— |
|
|
|
822 |
|
Selling, general and administrative |
|
|
5,952 |
|
|
|
2,946 |
|
|
|
— |
|
|
$ |
2,596 |
|
|
|
11,494 |
|
Provision for uncollectible accounts receivable |
|
|
666 |
|
|
|
3 |
|
|
|
— |
|
|
|
— |
|
|
|
669 |
|
Legal fee expense |
|
|
52 |
|
|
|
12 |
|
|
|
— |
|
|
|
308 |
|
|
|
372 |
|
Total operating costs, expenses and legal settlements, net |
|
|
17,566 |
|
|
|
6,897 |
|
|
|
195 |
|
|
|
2,904 |
|
|
|
27,562 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
992 |
|
|
|
829 |
|
|
|
(195 |
) |
|
|
(2,904 |
) |
|
|
(1,278 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(29 |
) |
|
|
10 |
|
|
|
— |
|
|
|
65 |
|
|
|
46 |
|
Other |
|
|
102 |
|
|
|
— |
|
|
|
— |
|
|
|
17 |
|
|
|
119 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(361 |
) |
|
|
— |
|
|
|
— |
|
|
|
(361 |
) |
Income (loss) before income taxes |
|
$ |
1,065 |
|
|
$ |
478 |
|
|
$ |
(195 |
) |
|
$ |
(2,822 |
) |
|
$ |
(1,474 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
401 |
|
|
$ |
508 |
|
|
$ |
— |
|
|
$ |
18 |
|
|
$ |
927 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
17 |
|
|
$ |
11 |
|
|
|
— |
|
|
$ |
121 |
|
|
|
149 |
|
Total |
|
$ |
19 |
|
|
$ |
11 |
|
|
$ |
— |
|
|
$ |
121 |
|
|
$ |
151 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
412 |
|
|
$ |
102 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
514 |
|
|